Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

Mazen Noureddin, Juan P. Frías, Guy Neff, K. Lucas, Cynthia Behling, Pierre Bédossa, Julie Dubourg, Doreen Chan, Mark Burch, Erica Fong, Brittany de Temple, Matt Minerva, Kim E. Barrett, Reshma Shringarpure, Erik J. Tillman, Tim Rolph, Andrew Cheng, Kitty Yale